Aptorum Group Files Amendment for Reverse Merger with DiamiR, Proposing Reverse Split and New Incentive Plan

summarizeSummary

Aptorum Group filed an S-4 amendment detailing its reverse merger with DiamiR Biosciences, including a proposed reverse stock split, reincorporation to Delaware, and a new stock incentive plan, all effectively guaranteed by the CEO's controlling vote.

check_boxKey Events

• Reverse Merger Update

  Provides further details on the proposed reverse merger with DiamiR Biosciences, which will result in existing Aptorum shareholders owning approximately 30% of the combined company, while DiamiR stockholders will own 70%.

• Shareholder Meeting & Proposals

  A special meeting is scheduled for June 9, 2026, to vote on the merger, a reverse stock split (share consolidation) with ratios from 2-1 to 10-1, domestication to Delaware, and a new 4.5 million share incentive plan.

• Guaranteed Approval

  The CEO, holding 86.71% of voting power, has signed an agreement to vote in favor of all proposals, effectively ensuring their passage.

• Financial Conditions Met

  Aptorum currently meets the closing conditions of $2.26 million cash and $1.644 million working capital, with $3.5 million cash and $3.6 million current assets as of December 31, 2025.

auto_awesomeAnalysis

This S-4 amendment provides updated details for Aptorum Group's proposed reverse merger with DiamiR Biosciences. The transaction is critical for Aptorum, which faces a "going concern" warning from its auditor and has stated it has "limited ability to continue its current operations indefinitely" without the merger. The merger will result in existing Aptorum shareholders owning approximately 30% of the combined entity, with DiamiR stockholders owning 70%, representing significant dilution. Key proposals include a reverse stock split (share consolidation) to maintain Nasdaq listing, a reincorporation to Delaware, and a new stock incentive plan. The company's CEO, holding 86.71% of voting power, has agreed to vote in favor of all proposals, ensuring their approval. The merger agreement's termination date has been extended to June 30, 2026, and Aptorum currently meets the cash and working capital conditions for closing.